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Aspirations: A Multi-Institutional Study
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BACKGROUND: Hürthle cell metaplasia is common in hyperplastic nodules, particularly within the setting of lymphocytic 
thyroiditis (LT). The Bethesda System for Reporting Thyroid Cytopathology indicates that it is acceptable to classify Hürthle 
cell–predominant fine-needle aspiration (HC FNA) specimens as atypia of undetermined significance (AUS) rather than 
suspicious for a Hürthle cell neoplasm (HUR) within the setting of multiple nodules or known LT. The goal of the current 
study was to address whether this approach is justified. METHODS: HC FNA specimens were identified and correlated with 
ultrasound and surgical pathology reports if available. Multinodularity was determined based on findings on macroscopic 
examination if imaging results were unavailable. RESULTS: A total of 698 HC FNA specimens were identified, including 576 
resected nodules, 455 of which (79%) were benign. The overall risk of malignancy for HUR was 27%, whereas the risk of 
malignancy for AUS was 10%. The mean size of the benign nodules was 2.1 cm on surgical resection specimens, with multiple 
nodules noted in 293 cases (64%) and histologic LT noted in 116 cases (25%). The mean size of the malignant nodules was 
2.8 cm, with multiple nodules and histologic LT noted in 74 cases (61%) and 22 cases (18%), respectively. The malignancy 
rate did not differ between solitary or multiple nodules (P = .52) or in the presence or absence of LT (P = .12). However, size 
did significantly differ between malignant and benign nodules (P < 0.01). CONCLUSIONS: The malignancy rate did not dif-
fer significantly in the presence of multiple nodules or LT, although the latter demonstrated a statistical trend. A diagnosis 
of AUS over HUR based solely on the presence of multinodularity is not warranted. Cancer Cytopathol 2020;128:68-75. 
© 2019 American Cancer Society. 
KEY WORDS: atypia of undetermined significance (AUS); fine-needle aspiration (FNA); follicular lesion of undetermined 
significance (FLUS); Hürthle cell; malignancy risk; multinodularity; thyroid.
INTRODUCTION
Hürthle cells are modified thyroid follicular cells that demonstrate oncocytic change, resulting in abundant 
eosinophilic granular cytoplasm due to the presence of numerous mitochondria.1 They often are associated 
with enlarged, round nuclei and central prominent nucleoli. Although oncocytic/Hürthle cell change initially 
was thought to be secondary to senescence, it now is believed to be a metaplastic change occurring in response 
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to cellular stress or changes in the microenvironment.1 
Hürthle cell metaplasia may be observed in a variety of 
nonneoplastic conditions such as autoimmune thyroiditis 
(including Hashimoto thyroiditis and Graves disease) and 
multinodular hyperplasia, although it also can be noted 
in both benign and malignant neoplasia.
Given this lack of specificity of Hürthle cell metapla-
sia, the accurate diagnosis of Hürthle cell–predominant 
fine-needle aspiration (HC FNA) specimens can be 
extremely problematic. Many cytologic features have been 
proposed for distinguishing nonneoplastic Hürthle cell 
nodules from neoplastic nodules as well as benign from 
malignant nodules, although to the best of our knowl-
edge no criteria have been widely accepted. These include 
cellularity,2-5 the amount of colloid,2-4,6-8 architecture (ie, 
macrofollicular sheets, crowded groups, singly dispersed 
cells),3,5,7,8 and nuclear pleomorphism or “dysplasia,”2,3,5-9 
among others. Given the inconsistency of cytologic features 
in the evaluation of HC FNA, it also has been suggested in 
The Bethesda System for Reporting Thyroid Cytopathology 
(TBSRTC) that clinicopathologic correlation can aid in 
evaluation. Specifically, TBSRTC states that it is acceptable 
to classify HC FNA as atypia of undetermined significance/
follicular lesion of undetermined significance (AUS/FLUS) 
rather than suspicious for a Hürthle cell neoplasm (HUR) 
within the setting of multiple nodules or known lympho-
cytic thyroiditis (LT).10 The goal of the current study was to 
address whether this approach is justified.
MATERIALS AND METHODS
Study Population and Data Acquisition
Approval from the institutional review board of each par-
ticipating institution was obtained. A search of HC FNA 
specimens was performed at each institution. Thyroid 
FNA cytologic preparations varied across institutions as 
well as within individual institutions (ie, due to operator 
preference), ranging from the routine use of both smear 
preparations (Diff-Quick staining or Papanicolaou stain-
ing) and liquid-based preparations to the use of only 
1 method. Cytologic diagnoses and patient demographics 
were recorded for each case. HC FNA specimens were 
categorized using TBSRTC with the following diagnos-
tic categories: benign, AUS, HUR, suspicious for malig-
nancy (SUS), and malignant.
When available, nodule size and the presence or 
absence of multiple nodules were documented based on 
ultrasound reports. Surgical pathology reports from cases 
with surgical follow-up were reviewed. Multinodularity 
was determined by findings on macroscopic examination 
if imaging results were unavailable. The histologic diag-
nosis, including the presence of LT, also was recorded for 
each case.
Surgical pathology diagnoses were classified using 
a binary system (ie, benign or malignant). All cases in 
the current study predated the introduction of the non-
invasive follicular thyroid neoplasm with papillary-like 
nuclear features category, and cases that had been diag-
nosed as follicular variant of papillary thyroid carcinoma 
(PTC) or PTC in which the subtype was not specified 
(PTC, NOS) were not reclassified. These cases were in-
cluded in the malignant category for the purposes of the 
current study, because the goal was to differentiate benign 
lesions from those that would require surgical resection 
within the setting of multinodularity.
Statistical Analysis
A Student t test or Fisher exact test was used to com-
pare differences in continuous and categorical variables, 
respectively (Prism 5; GraphPad, La Jolla, California). For 




Overall, a total of 698 HC FNA specimens from 677 
nodules were identified. The FNA diagnosis was benign 
in 12 cases (2%), AUS in 275 cases (39%), HUR in 
407 cases (58%), SUS in 3 cases (<1%), and malignant in 
1 case (<1%). A total of 576 nodules (85%) were surgically 
resected. Characteristics of resected and unresected cases 
were compared in a subset of cases for which sufficient in-
formation for the unresected nodules was available from 
the participating institutions (Table 1). Patients who did 
not undergo surgical resection were more likely to be older 
(P =  .021) and to have a preceding diagnosis of benign 
or AUS (P = .011 and P = .0075, respectively), whereas 
those with a preceding HUR diagnosis were more likely 
to undergo surgical resection (P = .0017). There was no 
significant difference noted between resected and unre-
sected cases with regard to the ultrasonographic size of the 
nodule, the presence of multinodularity, or the presence 
of multiple HC nodules sampled on FNA.
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The clinicopathologic features of all 576 cases 
that underwent surgical resection are summarized in 
Table 2. Of the resected nodules, 455 (79%) were classi-
fied as benign and 121 (21%) were classified as malignant. 
Sonographic assessment of multinodularity was available 
in 342 resected nodules overall (59%), including 261 
of 455 benign nodules (57%) and 81 of 121 malignant 
nodules (67%). Macroscopic assessment of multinodular-
ity was available in the remaining cases. The incidence of 
multinodularity was not found to be significantly different 
TABLE 1. Clinicopathologic Characteristics of Resected Versus Unresected Nodulesa 
Characteristic Resected Nodules N = 309a Unresected Nodules N = 93a P
Sex, no. (%)      
Female 237 (79) 75 (82) .77
Male 62 (21) 17 (18)
Age, y      
Mean 55 59 .021
Range 19-88 14-87  
FNA diagnosis, no. (%)      
Benign 1 (<1) 4 (4) .011
AUS 110 (36) 48 (52) .0075
HUR 194 (63) 41 (44) .0017
SUS 3 (1) 0 (0) 1.0
Malignant 1 (<1) 0 (0) 1.0
Mean tumor size on ultrasound, cm 2.4 2.3 .39
Nodularity, no. (%)b      
Multiple 202 (66) 52 (65) .89
Single 103 (34) 28 (35)
HC FNA of >1 nodule, no. (%) 10 (3) 1 (1) .47
Abbreviations: AUS, atypia of undetermined significance; FNA, fine-needle aspiration; HC FNA, Hürthle cell–predominant fine-needle aspiration; HUR, suspicious 
for a Hürthle cell neoplasm; SUS, suspicious for malignancy.
aOnly information from a subset of unresected cases was available for comparison.
bOf the patients for whom ultrasound findings were available.
TABLE 2. Clinicopathologic Characteristics of All Resected Nodules
Characteristic All Resected Nodules N = 576 Benign N = 455 Malignanta N = 121 P
Sex, no. (%)        
Female 462 (82)b 368 (83)b 94 (78) .23
Male 104 (18)b 77 (17)b 27 (22)
Age, y        
Mean 54 54 55 .47
Range 19-88 19-88 15-87  
FNA diagnosis        
Benign 7 (1) 5 (1) 2 (2) .64
AUS 210 (36) 189 (42) 21 (17) <.01
HUR 355 (62) 260 (57) 95 (79) <.01
SUS 3 (<1) 1 (<1) 2 (2) .12
Malignant 1 (<1) 0 (0) 1 (1) .21
HC FNA of >1 nodule, no. (%) 10 (2) 10 (2) 0 (0) .13
Mean tumor size on ultrasound, cm 2.5 2.3 2.8 <.01
Mean macroscopic tumor size, cm 2.2 2.1 2.8 <.01
Nodularity, no. (%)c        
Multiple 367 (64) 293 (64) 74 (61) .52
Single 209 (36) 162 (36) 47 (39)
LT, no. (%)        
Present 138 (24) 116 (25) 22 (18) .12
Absent 438 (76) 339 (75) 99 (82)
Concurrent MN and LT, no. (%)        
Present 84 (15) 68 (15) 16 (13) .77
Absent 492 (85) 387 (85) 105 (87)
Abbreviations: AUS, atypia of undetermined significance; FNA, fine-needle aspiration; HC FNA, Hürthle cell–predominant fine-needle aspiration; HUR, suspicious 
for a Hürthle cell neoplasm; LT, lymphocytic thyroiditis; MN, multinodularity; SUS, suspicious for malignancy.
P values were based on a comparison of benign and malignant nodules.
aAll nonbenign nodules were included in this group, including those cases previously diagnosed as follicular variant of papillary thyroid carcinoma.
bTen patients had 2 different nodules with a preceding HC FNA.
cMultinodularity was determined based on ultrasound or macroscopic findings.
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between nodules with sonographic or macroscopic assess-
ment (65% and 62%, respectively; P = .48).
Benign Nodules
Of the 445 patients with benign nodules, 368 (83%) were 
female and 77 (17%) were male. The mean age of the 
patients was 54 years (range, 19-88 years). The preced-
ing FNA diagnosis was benign in 5 cases (1%), AUS in 
189 cases (42%), HUR in 260 cases (57%), SUS in 1 
case (<1%), and malignant in none of the cases (0%). 
All 10 patients who had >1 nodule with a preceding 
HC FNA specimen were found to have benign find-
ings on surgical resection. The mean size of the benign 
nodules was 2.3  cm by ultrasound and 2.1  cm on sur-
gical resection. Multiple nodules were identified in 293 
cases overall (64%), including 167 of 261 cases (64%) 
for which sonographic assessment was available and 126 
of 194 cases (65%) that were evaluated macroscopically. 
On histopathologic examination, there were 264 follicu-
lar adenomas or adenomatous nodules  (58%) (Fig. 1), 
166 hyperplastic nodules (36%), 2 infarcted nodules 
(<1%), 1 hyalinizing trabecular tumor (<1%), and 1 par-
athyroid adenoma (<1%). The remaining 21 cases (5%) 
demonstrated LT only without a dominant nodule 
documented, although 116 cases overall (25%) had his-
tologic LT.
Malignant Nodules
The mean age of the patients with malignant nodules 
was 55 years (range, 15-87 years), with 94 females (78%) 
and 27 males (22%). The preceding FNA diagnosis was 
benign in 2 cases (2%), AUS in 21 cases (17%), HUR 
in 95 cases (79%), SUS in 2 cases (2%), and malignant 
in 1 case (1%). Compared with benign nodules, malig-
nant nodules were more likely to have been diagnosed 
as HUR on FNA (P < .01) (Table 2). The overall risk of 
malignancy (ROM) for HUR was 27% (95 of 355 cases), 
whereas the ROM for AUS was 10% (21 of 210 cases).
The mean size of the nodules was 2.8 cm on both 
ultrasound and surgical resection. Sonographic and his-
topathologic sizes were significantly different between 
malignant and benign nodules (P < .01 for both). Of the 
malignant nodules, 65 were follicular carcinomas (includ-
ing Hürthle cell carcinomas) (54%), 47 were PTC (39%), 
6 were poorly differentiated thyroid carcinomas (5%) 
(Fig. 2), 2 were medullary carcinomas (2%), and 1 was an 
Figure 1. Example of a benign nodule in the current study 
cohort. (A) The preceding fine-needle aspiration specimen had 
abundant Hürthle cells that were singly dispersed and in clusters. 
(B and C) The surgical resection specimen demonstrated an 
adenomatous nodule with Hürthle cell change.
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undifferentiated carcinoma (1%). Of the 47 PTC cases, 
24 were the follicular variant of PTC (20%), 16 were non-
follicular variants (including classic, oncocytic, and solid 
variants) (13%), and 7 did not have a subtype specified 
(PTC, NOS) (6%). Twenty-two cases (18%) demon-
strated histologic LT. Multiple nodules were detected in 74 
cases overall (61%). These included 55 of 81 nodules for 
which ultrasound evaluation was available (68%) and 19 
of 40 nodules that were evaluated macroscopically (48%). 
Among the entire cohort, there was not a statistically 
significant difference noted with regard to the malignancy 
rate regardless of the presence or absence of LT, although 
there was a weak statistical trend (P =  .12). The malig-
nancy rate also did not differ within the setting of solitary 
or multiple nodules (P = .52) or when considering con-
current multinodularity and LT (P = .77).
DISCUSSION
Hürthle cell metaplasia is common in thyroid nodules 
and can be observed in both malignant and benign thy-
roid disease, including nonneoplastic conditions such as 
LT or multinodular hyperplasia. For this reason, the eval-
uation of HC FNA can be challenging, especially given 
the lack of specificity of morphologic features in identi-
fying neoplasia or differentiating benign from malignant 
nodules in cytologic preparations. To aid in this differ-
ential, TBSRTC has recommended that clinical features 
can be useful in the evaluation of HC FNA. In particular, 
TBSRTC has offered that it is acceptable to diagnosis HC 
FNA as AUS/FLUS rather than HUR in a patient with 
multiple thyroid nodules or LT.10
In the current multi-institutional study, a large cohort 
of HC FNA specimens was evaluated to determine whether 
this approach suggested by TBSRTC is justified. Overall, 
we found that 79% of the 576 resected Hürthle cell– 
predominant nodules were benign, whereas the remaining 
21% were malignant. More specifically, the ROM for the 
HC FNA specimens diagnosed as HUR was 27%, whereas 
that of specimens diagnosed as AUS was 10%. The ROMs 
for AUS with a predominance of Hürthle cells (AUS-HC) 
and HUR have been highly variable in the literature, with 
rates ranging from 0% to 26% for AUS-HC11-16 and from 
14% to 45% for HUR.2,6,7,15,17-28 However, the median 
ROMs for AUS-HC and HUR among these studies were 
11% and 23%, respectively, similar to the findings we 
observed in the cohort in the current study. Our study 
did not specifically address the underlying rationale for 
Figure 2. Example of a malignant nodule in the current study 
cohort. (A) The fine-needle aspiration specimen was composed 
of cells with abundant oncocytic cytoplasm, round nuclei, 
and prominent nucleoli. (B and C) The subsequent surgical 
resection specimen demonstrated a widely invasive, poorly 
differentiated thyroid carcinoma.
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classifying thyroid aspirates as AUS-HC rather than HUR. 
The findings indicated that the number of nodules present 
should not determine this distinction; however, other pa-
rameters such as overall cellularity, abundance of colloid, 
and cell cohesiveness undoubtedly factor into the classifi-
cation of Hürthle cell nodules and are able to stratify such 
lesions to a limited extent.
Among benign nodules, we found that the incidence 
of multinodularity was 64% compared with 61% in ma-
lignant nodules (P = .52). To the best of our knowledge, 
prior studies evaluating the significance of multinodular-
ity in HC FNA specimens have been limited. However, 
one study by Turanli et al did not find a statistically signif-
icant difference in multinodularity in benign (53%) ver-
sus malignant (43%) nodules.29 Another study by Sclabas 
et al evaluated multinodularity within the setting of all in-
determinate FNA specimens, in which again no difference 
was found with regard to malignant nodules.22 In the his-
tologic evaluation of follicular neoplasms, including both 
Hürthle cell and non–Hürthle cell lesions, the number 
of nodules has been associated with ROM.23 However, 
among all thyroid nodules, the significance of multinod-
ularity on ROM has been highly variable in the literature. 
In a meta-analysis of 14 studies, a slightly lower ROM 
was noted within the setting of multinodular goiter, 
although this difference only was observed when including 
studies outside of the United States from iodine-deficient 
areas.30 Although we found no overall difference in ROM 
between Hürthle cell nodules in solitary or multinodular 
thyroids, all 10 patients in the current study cohort who 
had >1 nodule with a preceding HC FNA specimen were 
found to have benign findings on surgical resection. This 
finding in a limited number of cases did not reach the 
level of statistical significance, but at least raises the pos-
sibility that an AUS-HC diagnosis may be warranted in 
the case of a patient with multiple Hürthle cell–rich nod-
ules (vs multiple non–Hürthle cell or just radiographically 
detected nodules). However, a caveat to this possibility 
is that there potentially could be sampling of “multiple” 
nodules, which in fact are different areas of a single large 
and/or irregular lesion or a multifocal tumor. Although 
close radiologic correlation may help with this distinction, 
in some cases the distinction may not always be possi-
ble. A larger series of such cases is needed to examine this 
specific uncommon scenario further.
In addition, in the current study, we also evaluated 
the rate of histologic LT among benign nodules (25%) 
compared with malignant nodules (18%), although the 
difference we observed did not reach statistical signifi-
cance (P = .12). This finding is similar to those of prior 
studies, which also did not find a difference in the rate 
of LT among benign and malignant nodules with a pre-
ceding HC FNA specimen.19,31 In the study by Canberk 
et al, histologic LT was identified in 53 of 213 thyroids 
with benign nodules (25%) and in 14 of 56 malignant 
thyroids (25%).31 Roh et al, who included both clinical, 
radiologic, and histologic criteria for Hashimoto thyroid-
itis, also did not find a statistical difference with regard to 
the ROM among nodules with a preceding HUR FNA 
specimen (25.2 vs 9.5%; P  =  .081).19 However, given 
that the ROM for cases without Hashimoto thyroiditis 
more closely approached the expected ROM for AUS/
FLUS,10 the authors suggested that it may be more ap-
propriate to diagnose these HC FNA cases as AUS/FLUS 
rather than HUR.19 When using only cytologic findings 
in HC FNA specimens that are suggestive of LT (ie, with 
markedly increased lymphocytes), there also have been 
variable results reported in the prediction of ROM for 
HC FNA specimens.2,9 Although not the primary focus 
of the current study, the data presented herein reinforced 
the idea that the impact of LT on the ROM for Hürthle 
cell–rich aspirates is limited, demonstrating only a weak 
statistical trend that did not rise to the level of statisti-
cal significance in multiple studies. Nevertheless, even a 
minimal impact on ROM within the setting of LT is con-
sistent with favoring an AUS diagnosis over HUR within 
this context.
Limitations of the current study included variabil-
ity in the assessment of multinodularity. Although the 
majority of cases had imaging results available, a subset 
relied on macroscopic pathologic examination, and it 
was unclear whether the latter would have had clinically 
or radiologically detectable multinodularity at the time 
of FNA. Limitations in data availability also prohibited 
further assessment of more granular findings, such as the 
number and size of additional thyroid nodules. In addi-
tion, because our criterion for LT included only histo-
logic examination, the results of the current study may 
not have captured cases with reporting bias (ie, LT present 
but not documented in the surgical pathology report). In 
addition, histologic LT can be a somewhat nonspecific 
finding and is, of course, only known after surgical resec-
tion is performed. The inclusion instead of patients with 
true autoimmune thyroiditis or convincing radiologic 
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evidence of thyroiditis may be more clinically relevant. 
However, limited access to detailed information in the 
patient medical records served as a barrier to providing a 
more complete characterization of these patients. Finally, 
given that there was not a central review of cytology slides, 
there likely was some variability in the criteria for FNA 
diagnosis between institutions as well as individual cyto-
pathologists. Subjectivity with regard to what constitutes 
a predominance of Hürthle cells beyond what is accept-
able for benign/reactive conditions could have affected 
the AUS threshold and overall case selection. However, 
pooling of the data from all institutions may have mini-
mized any potential biases in diagnostic criteria.
The results of the current study demonstrated that 
multinodularity and LT were not significantly different in 
benign and malignant Hürthle cell–predominant nodules 
(including cases that currently are classified as noninva-
sive follicular thyroid neoplasm with papillary-like nu-
clear features, which still require surgical resection). The 
large, multi-institutional data set in the current study sug-
gests that the option in TBSRTC for downgrading HC 
FNA specimens from HUR to AUS solely on the basis 
of multinodularity generally is unwarranted. The specific 
scenario of multiple Hürthle cell nodules may represent 
an exceptional circumstance warranting further study 
along with other factors contributing to risk stratification 
among Hürthle cell–rich thyroid aspirates.
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